• ABOUT
  • PRIVACY
  • CONTACT
  • ADVERTISE
No Result
View All Result
KeralaNews 24x7
Friday, July 4, 2025
  • HOME
  • NEWS
  • ENTERTAINMENT
  • CRYPTO
  • SPORTS
    • OLYMPIC
    • CRICKET
    • FOOTBALL
    • KABADDI
    • BASKETBALL
    • TENNIS
    • WWE
  • TECHNOLOGY
  • HEALTH
  • EVENTS
  • DEALS
    • SPECIAL DEALS
  • BLOG
    • BUSINESS
    • FINANCE
    • DIGITAL MARKETING
    • EDUCATION
    • LIFE STYLE
    • REAL ESTATE
    • ART
    • ADULT
    • CASINO
    • FASHION
    • GAMES
    • LAW AND ORDER
    • TRAVEL
  • HOME
  • NEWS
  • ENTERTAINMENT
  • CRYPTO
  • SPORTS
    • OLYMPIC
    • CRICKET
    • FOOTBALL
    • KABADDI
    • BASKETBALL
    • TENNIS
    • WWE
  • TECHNOLOGY
  • HEALTH
  • EVENTS
  • DEALS
    • SPECIAL DEALS
  • BLOG
    • BUSINESS
    • FINANCE
    • DIGITAL MARKETING
    • EDUCATION
    • LIFE STYLE
    • REAL ESTATE
    • ART
    • ADULT
    • CASINO
    • FASHION
    • GAMES
    • LAW AND ORDER
    • TRAVEL
No Result
View All Result
News 24x7
No Result
View All Result

Glenmark and Pfizer launch new oral drug for atopic dermatitis in India

Nishita Masih by Nishita Masih
1 year ago
Reading Time: 3 mins read
0
0
0
SHARES
24
VIEWS
FBXLinkedinWhatsAppTelegram

Glenmark Pharmaceuticals Ltd. and Pfizer India have announced a partnership to launch a new oral drug for the treatment of moderate-to-severe atopic dermatitis (AD) in India. The drug, abrocitinib, is the first of its kind in the country and has been approved by various regulatory agencies, including the US FDA and the European Medicines Agency.

What is atopic dermatitis and how does abrocitinib work?

Atopic dermatitis is a chronic skin disease that causes inflammation, itching, redness, and dryness of the skin. It affects about 5.9% of adults in India, of which 4.4% suffer from a severe form of the disease. The symptoms of AD can have a significant impact on the quality of life and mental health of the patients and their caregivers.

atopic dermatitis
atopic dermatitis

Abrocitinib is a Janus kinase 1 (JAK1) inhibitor, which blocks the activity of a protein that is involved in the inflammatory response of the skin. By doing so, abrocitinib reduces the symptoms of AD, such as itching, swelling, and scaling. Abrocitinib also improves the skin barrier function and prevents infections and complications.

Abrocitinib is an oral tablet that is taken once daily. It has been shown to be effective and safe in clinical trials involving more than 2,500 patients with moderate-to-severe AD. Abrocitinib has also been compared with other treatments for AD, such as topical steroids and dupilumab, and has demonstrated superior or comparable results.

How will the partnership between Glenmark and Pfizer benefit the patients?

Glenmark and Pfizer will co-market abrocitinib in India under the brand names JABRYUS and CIBINQO, respectively. The partnership will leverage the expertise and capabilities of both companies to make the drug available and accessible to the patients and physicians across the country.

Glenmark is a leader in the dermatology therapy segment in India, with a portfolio of over 80 products and a network of over 20,000 dermatologists. Glenmark also has a strong presence in the rural and semi-urban markets, where the prevalence of AD is high.

Pfizer is a global pharmaceutical company that has developed and manufactured abrocitinib. Pfizer has a rich heritage and experience in the field of inflammation and immunology, with several innovative and breakthrough therapies in its pipeline. Pfizer also has a robust distribution and supply chain system in India, with a reach of over 50,000 pharmacies.

The collaboration between Glenmark and Pfizer will ensure that abrocitinib is made available to the patients at an affordable price and with a high quality standard. The companies will also conduct awareness and education programs for the patients and the medical fraternity, to increase the diagnosis and treatment of AD in India.

What are the other markets and achievements of abrocitinib?

Abrocitinib is available in over 35 markets globally, including the US, Japan, and China, under the brand name CIBINQO. India is the first country to get access to the drug through the partnership between Glenmark and Pfizer.

Abrocitinib has received several awards and recognitions for its innovation and impact. It has been named as one of the top 10 breakthrough therapies of 2023 by the Scrip Awards, and as one of the best inventions of 2023 by Time Magazine. It has also been granted the Breakthrough Therapy designation by the US FDA, and the Priority Medicines designation by the European Medicines Agency.

Abrocitinib is expected to transform the lives of millions of patients with moderate-to-severe AD, who have been suffering from the debilitating and distressing symptoms of the disease. Abrocitinib is the first oral advanced systemic treatment for AD in India, and will offer a convenient and effective option for the patients and the doctors.

ShareTweetShareSendShare
Nishita Masih

Nishita Masih

Nishita Maish is a senior content manager, blending creativity with strategic insight to craft compelling narratives that captivate audiences. With a passion for storytelling and a knack for digital engagement, she has elevated brands and content strategies to deliver lasting impact in the ever-evolving digital world.

Related Posts

smriti mandhana batting india women cricket england 2024

India Eye Another Commanding Win as Mandhana Shines and Harmanpreet Eyes Return

18 hours ago
trump and elon musk 2025 debate stage

Trump Turns on Musk, Calls for Federal Probe as Crypto-Fueled Feud Boils Over

19 hours ago
hdfc mutual fund innovation fund 2025 nfo

HDFC Bets Big on Disruptive Growth with Launch of Innovation Fund

2 days ago
Lee Seo Yi South Korean actress 2025 Instagram tribute

South Korean Actress Lee Seo Yi Dies at 43, Leaves Behind a Legacy of Grace and Talent

2 days ago
us dollar index chart 2025

Dollar’s Steepest Slide in Over 50 Years Rings Global Alarm Bells

2 days ago
Lee Jung Jae Squid Game 3 Netflix global premiere

Squid Game 3 Shatters Global Streaming Records, Becomes Netflix’s Fastest-Rising K-Drama Ever

3 days ago
Michael Saylor bitcoin keynote BTC Prague 2024

Strategy’s $531.9 Million Bitcoin Grab Lifts Holdings to 597,325 BTC as Capital Engine Roars

3 days ago
Lhuan-dre Pretorius batting 2025 Zimbabwe Test

Teen Prodigies Shine Bright as Lhuan-dre Pretorius and Smriti Mandhana Etch Their Names in Cricket History

4 days ago

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

No Result
View All Result

ADVERTISEMENTS

(adsbygoogle = window.adsbygoogle || []).push({});

POPULAR ARTICLES

online

5 Best Online Journals to Get Your Psychology Dissertation Published

6 years ago
iPhone Users

Apple to Pay Millions of iPhone Users for Slowing Down Their Devices

2 years ago
Apple

Apple to Launch AI-Powered Coding Tool for iOS Developers

1 year ago
mediatek dimensity 9500 geekbench processor chipset

MediaTek’s Dimensity 9500 Surfaces on Geekbench With Cortex-X930 Core and Mali-G1-Ultra GPU

3 weeks ago
eSports

Just How Big Will eSports Be?

8 years ago
Iontophoresis Device

Iontophoresis Device, the Best Treatment for Excessive Sweating

8 years ago
NOW Entertainment soon to Start Selling American Hustle82 Apparel

NOW Entertainment soon to Start Selling American Hustle82 Apparel

8 years ago
E-cigs Products in Classrooms

Is It Right to Ban the Juul and Other E-cigs Products in Classrooms?

8 years ago
Ryan Van Wagenen

Ryan Van Wagenen Expects Continued Growth for the Silicon Slopes

7 years ago
Working Remotely: Benefits for Employers and Employees

Working Remotely: Benefits for Employers and Employees

7 years ago
Facebook Twitter Youtube

ABOUT US

The KeralaNews 24×7 website is for desi entertainment lovers across India, USA and UK. We often cover breaking News & Trending topics in India and have been referenced by numerous media outlets. Follow us on our Social media profiles for the latest updates and news.

Contents produced in this website are subjected to DigitalCopyRight Law.

© 2023 KeralaNews 24×7 – Website Designed by VISION

WEBSITE STATS

  • Google News Approved
  • 1,00,000 Traffic/Month
  • Domain Authority – 25
  • 70% Traffic from Google

ADVERTISE WITH US

If you are looking to advertise your business or website, feel free to contact us at ceo.keralanews247@gmail.com

We accept following form of advertisements,

  • Banner Ads
  • Contextual Links
  • Guest Posts
  • Sponsored Posts

SEARCH

No Result
View All Result

MORE INFO

  • ABOUT
  • PRIVACY
  • CONTACT
  • ADVERTISE

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • NEWS
  • ENTERTAINMENT
  • CRYPTO
  • SPORTS
    • OLYMPIC
    • CRICKET
    • FOOTBALL
    • KABADDI
    • BASKETBALL
    • TENNIS
    • WWE
  • TECHNOLOGY
  • HEALTH
  • EVENTS
  • DEALS
    • SPECIAL DEALS
  • BLOG
    • BUSINESS
    • FINANCE
    • DIGITAL MARKETING
    • EDUCATION
    • LIFE STYLE
    • REAL ESTATE
    • ART
    • ADULT
    • CASINO
    • FASHION
    • GAMES
    • LAW AND ORDER
    • TRAVEL

© 2023 KeralaNews 24x7 - Website Designed by VISION

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.